The Evelyn Trust

The Evelyn Trust

The Evelyn Trust was established in 1920 under the will of Edward Evelyn, a Cambridgeshire landowner and descendant of the 17th-century diarist John Evelyn. The endowment initially derived from agricultural and residential property holdings in central Cambridge, including assets near the city's historic core. The Trust converted its charitable status to a company limited by guarantee in 1999 while maintaining its original mission: advancing medical research and public health within Cambridgeshire and the broader East of England region. Grant-making focuses on three areas: medical research grants to institutions including the University of Cambridge and Anglia Ruskin University, health and wellbeing projects operated by local NHS trusts and community organizations, and small capital awards for equipment and facilities. The Trust does not make direct equity investments or fund commitments—it operates as a pure grant-maker, not a venture investor. Named beneficiaries have included Cambridge University Hospitals NHS Foundation Trust for neonatal equipment, the Cambridge Institute for Medical Research for early-career fellowships, and East Anglia's Children's Hospices for palliative care expansion. Geographic coverage remains tightly bound to Cambridgeshire, Norfolk, Suffolk, Essex, Hertfordshire, and Bedfordshire (per the firm's trustee reports). Governance rests with a board of trustees chaired by Dr. Andrew P. B. Wiles, a Cambridge-based retired consultant physician, alongside a mix of academics and professionals drawn from the University of Cambridge medical and scientific community. The Trust maintains no external fund-management relationship—its endowment assets are managed internally under trustee direction, primarily in listed securities and UK property. It runs no adjacent venture arm, co-investment club, or philanthropic vehicle beyond its single grant-making entity. The Trust's structural differentiator is its extreme geographic and institutional concentration: nearly all grants flow to Cambridge-based researchers and NHS bodies. This creates a high-touch, relationship-driven grant-making model where trustees personally evaluate applications and often serve on overlapping boards with university and hospital leadership. For an institutional allocator, the Trust is irrelevant as a co-investment partner; for a medical-research foundation mapping the Cambridge life-sciences ecosystem, it functions as a consistent early-stage translational-research funder (per public record).